 Connection
Alexis Leal to Neoplasms
This is a "connection" page, showing publications Alexis Leal has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.330 |
|
|
|
-
Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014 Jun 15; 120(12):1890-7.
Score: 0.177
-
Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295.
Score: 0.083
-
O'Sullivan CC, Van Houten HK, Sangaralingham LR, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ. Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2018 03; 16(3):294-299.
Score: 0.058
-
Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2015 Jan; 23(1):55-9.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|